The effects of reformulation: improved therapeutic index.
Antimuscarinic agents are the treatment of choice for overactive bladder syndrome. Due to the development of novel delivery systems, extended-release formulations of oxybutynin, tolterodine, and trospium chloride are now available. In addition to the convenience of once-daily dosing, the new formulations of these commonly prescribed agents have improved their therapeutic index, striking a better balance between efficacy and tolerability.
MacDiarmid
Scott
S
Bladder Control and Pelvic Pain Center, Greensboro, NC 27403, USA. smacdiarmid@allianceurology.com
Sandage
Bobby W
BW
Malhotra
Bimal K
BK
D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D001561:Benzilates; D002626:Chemistry, Pharmaceutical; D003408:Cresols / Q000627:therapeutic use*; D006801:Humans; D008333:Mandelic Acids / Q000627:therapeutic use*; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D009662:Nortropanes / Q000627:therapeutic use*; D010665:Phenylpropanolamine / Q000627:therapeutic use*; D000068737:Tolterodine Tartrate; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D001561:Benzilates; D003408:Cresols; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D009662:Nortropanes; C003330:trospium chloride; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin